# Pinealon dosage guide

> Review Pinealon dosage information by administration route, with source-linked dose and schedule details.

Canonical: https://pepflow.app/peptides/pinealon/dosage/

Compare Pinealon capsule schedules with injection patterns, including their different strengths, frequencies and course lengths. Calculate volume and syringe units using your own vial inputs.

[Full Pinealon library reference](<https://pepflow.app/peptides/pinealon/>)

## Pinealon dosage chart

This summary table compares available dose amounts and schedules by administration route.

| Route | Dose | Frequency & duration |
| --- | --- | --- |
| Oral | 100 mcg | Twice daily · 14 days |
| Injectable | ~1 mg | Daily · ~20 days |

## Pinealon dosage by administration route

### Pinealon oral dosage

The documented oral schedule is one capsule containing 100 mcg twice daily for 14 days, totaling 200 mcg per day. Capsule strength must match this preparation; it is not the same as the milligram amounts listed for other products.[\[1\]](<https://pepflow.app/peptides/pinealon/dosage/#source-1>)

Pinealon is the Glu-Asp-Arg tripeptide associated with neuronal stress-response signaling. Capsule products and injectable preparations need separate formulation-specific amounts.[\[2\]](<https://pepflow.app/peptides/pinealon/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/pinealon/dosage/#source-3>) [\[4\]](<https://pepflow.app/peptides/pinealon/dosage/#source-4>) [\[5\]](<https://pepflow.app/peptides/pinealon/dosage/#source-5>)

### Pinealon injectable dosage

Reported-use amounts for Pinealon are ~1 mg per administration, daily, for approximately 20 days. A reported subcutaneous schedule uses 1–5 mg daily for ten days, followed by an unspecified break measured in months. This is separate from the 100 mcg capsule schedule and from longer injectable patterns; the break length is not defined.[\[11\]](<https://pepflow.app/peptides/pinealon/dosage/#source-11>) [\[12\]](<https://pepflow.app/peptides/pinealon/dosage/#source-12>)

Pinealon is the Glu-Asp-Arg tripeptide associated with neuronal stress-response signaling. Capsule products and injectable preparations need separate formulation-specific amounts.[\[4\]](<https://pepflow.app/peptides/pinealon/dosage/#source-4>) [\[3\]](<https://pepflow.app/peptides/pinealon/dosage/#source-3>) [\[5\]](<https://pepflow.app/peptides/pinealon/dosage/#source-5>) [\[11\]](<https://pepflow.app/peptides/pinealon/dosage/#source-11>)

### Frequency and timing

Morning is the listed injection timing. Capsules are taken twice daily according to their separate preparation-specific schedule.[\[6\]](<https://pepflow.app/peptides/pinealon/dosage/#source-6>) [\[2\]](<https://pepflow.app/peptides/pinealon/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/pinealon/dosage/#source-3>) [\[1\]](<https://pepflow.app/peptides/pinealon/dosage/#source-1>) [\[11\]](<https://pepflow.app/peptides/pinealon/dosage/#source-11>)

### Cycle length and breaks

Oral: 14 days. Injectable: ~20 days. A standard break interval between courses is not established.[\[1\]](<https://pepflow.app/peptides/pinealon/dosage/#source-1>) [\[11\]](<https://pepflow.app/peptides/pinealon/dosage/#source-11>)

## Pinealon dosage calculator

Convert your chosen Pinealon amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.

For preparation terms and concentration basics, see the [reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>). Follow the arithmetic in the [concentration calculation walkthrough](<https://pepflow.app/blog/how-to-calculate-final-concentration/>).

## Pinealon safety and side effects

### Approval and product quality

Pinealon is not an FDA-approved drug.[\[6\]](<https://pepflow.app/peptides/pinealon/dosage/#source-6>) [\[8\]](<https://pepflow.app/peptides/pinealon/dosage/#source-8>) [\[9\]](<https://pepflow.app/peptides/pinealon/dosage/#source-9>) [\[10\]](<https://pepflow.app/peptides/pinealon/dosage/#source-10>)

### Side effects and long-term safety

Pharmacokinetics, interactions, reproductive safety and long-term repeated-cycle effects remain unclear. Sleep and mood effects are relevant concerns for oral neuroactive preparations.[\[2\]](<https://pepflow.app/peptides/pinealon/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/pinealon/dosage/#source-3>) [\[4\]](<https://pepflow.app/peptides/pinealon/dosage/#source-4>) [\[7\]](<https://pepflow.app/peptides/pinealon/dosage/#source-7>)

### Route-specific dosing limits

Sparse modern human data make neurologic context and product identity important. Reported-use injectable schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[\[2\]](<https://pepflow.app/peptides/pinealon/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/pinealon/dosage/#source-3>) [\[4\]](<https://pepflow.app/peptides/pinealon/dosage/#source-4>) [\[7\]](<https://pepflow.app/peptides/pinealon/dosage/#source-7>) [\[12\]](<https://pepflow.app/peptides/pinealon/dosage/#source-12>) [\[11\]](<https://pepflow.app/peptides/pinealon/dosage/#source-11>)

## Common Pinealon dosage questions

### Can Pinealon doses be transferred between routes?

No. Each route and formulation has its own exposure and administration requirements. Use the dose information for the exact presentation rather than copying a tablet, injection or local-product amount to another route.[\[6\]](<https://pepflow.app/peptides/pinealon/dosage/#source-6>) [\[2\]](<https://pepflow.app/peptides/pinealon/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/pinealon/dosage/#source-3>)

### What dosage is listed for Pinealon?

The documented oral schedule is one capsule containing 100 mcg twice daily for 14 days, totaling 200 mcg per day.[\[1\]](<https://pepflow.app/peptides/pinealon/dosage/#source-1>)

### Does Pinealon have a standard cycle or break interval?

Oral: 14 days. Injectable: ~20 days. A standard break interval between courses is not established.[\[1\]](<https://pepflow.app/peptides/pinealon/dosage/#source-1>) [\[11\]](<https://pepflow.app/peptides/pinealon/dosage/#source-11>)

## Sources

- [\[1\] **\[Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades\].** Advances in Gerontology, 2012. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/22708445/>)
- [\[2\] **\[Neuroprotective effects of peptides bioregulators in people of various age\].** Advances in Gerontology, 2013. review.](<https://pubmed.ncbi.nlm.nih.gov/24738258/>)
- [\[3\] **Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.** Rejuvenation Research, 2011 Oct. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/21978084/>)
- [\[4\] **Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.** Biochemistry (Mosc), 2011 Nov. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/22117547/>)
- [\[5\] **Pinealon protects the rat offspring from prenatal hyperhomocysteinemia.** International Journal of Clinical and Experimental Medicine, 2012. animal.](<https://pubmed.ncbi.nlm.nih.gov/22567179/>)
- [\[6\] **Search Drugs@FDA for Pinealon** U.S. Food and Drug Administration. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[7\] **Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture.** Bull Exp Biol Med, 2011 Nov. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/22803060/>)
- [\[8\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[9\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[10\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[11\] **PepFlow peptide cheat sheet — reported-use and product-orientation reference (not clinical research)** PepFlow. reference catalog.](<https://pepflow.app/peptide-cheat-sheet/>)
- [\[12\] **Pinealon — Everything Peptide reported protocol (educational reference, not clinical evidence)** Everything Peptide. reference catalog.](<https://everythingpeptide.com/protocol-pinealon.html>)

[Full Pinealon library reference →](<https://pepflow.app/peptides/pinealon/>)

## Related

- [Pinealon Peptide](<https://pepflow.app/peptides/pinealon/>)
- [Peptide reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>)
- [How to Calculate Final Concentration: A Practical Guide](<https://pepflow.app/blog/how-to-calculate-final-concentration/>)
- [Peptide Cheat Sheet](<https://pepflow.app/peptide-cheat-sheet/>)
